A
Agilent Technologies, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers):
breedte van houders +10.0% ·
aandelenstroom -0.4% ·
netto nieuwe posities +4.5%
· formule
Fragmentatie van eigendom: meer houders, kleiner totaalbelang
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 152.88K | $24.44M | n/a | n/a |
| Q2 2026 | 164 | +3 | 194.45M | $25.84B | +9 | −7 |
| Q1 2026 | 165 | -3 | 181.10M | $20.68B | +3 | −7 |
| Q4 2025 | 167 | +1 | 200.20M | $27.23B | +3 | −1 |
| Q3 2025 | 22 | +2 | 109.95M | $14.10B | +3 | −2 |
| Q2 2025 | 18 | -1 | 102.37M | $12.08B | n/a | −1 |
| Q1 2025 | 16 | -1 | 41.13M | $4.81B | n/a | −1 |
| Q4 2024 | 17 | +1 | 41.24M | $5.54B | +2 | −1 |
| Q3 2024 | 15 | -1 | 26.67M | $3.96B | +1 | −2 |
| Q2 2024 | 16 | n/a | 29.82M | $3.86B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 34.04M | +0.1% | $4.37B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passief) | 26.14M | +1.0% | $3.36B | 0.1% | ▲ Add | 2 | SEC ↗ ×21 |
| 3 | State Street Global Advisors ✦ (passief) | 12.44M | -0.1% | $1.60B | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 9.38M | +4.8% | $1.20B | 0.2% | ▲ Add | 6 | SEC ↗ ×8 |
| 5 | Geode Capital Management ✦ (passief) | 7.40M | +1.1% | $945.98M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | JPMorgan Chase ✦ | 4.51M | n/a | $579.37M | 0.0% | n/c | 1 | SEC ↗ ×32 |
| 7 | Morgan Stanley ✦ | 4.35M | n/a | $558.28M | 0.0% | n/c | 1 | SEC ↗ ×19 |
| 8 | Goldman Sachs Group ✦ | 2.53M | n/a | $324.63M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | AQR Capital Management ✦ | 1.68M | -17.7% | $209.32M | 0.1% | ▼ Trim | 6 | SEC ↗ ×6 |
| 10 | Marshall Wace ✦ | 1.59M | +5.3% | $204.32M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 1.52M | +38.7% | $195.19M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 12 | PRIMECAP Management ✦ | 1.41M | -7.7% | $181.32M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 1.12M | -7.6% | $143.53M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 14 | T. Rowe Price ✦ | 445.41K | -7.4% | $57.17M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | Arrowstreet Capital ✦ | 425.38K | +91.6% | $54.60M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 392.66K | -76.2% | $50.40M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | Point72 Asset Management ✦ | 260.12K | Nieuw | $33.39M | 0.1% | New | 1 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 133.59K | -27.7% | $17.15M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 73.72K | -83.7% | $9.46M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Bridgewater Associates ✦ | 47.70K | Nieuw | $6.12M | 0.0% | New | 1 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 42.80K | +256.4% | $5.49M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Fisher Asset Management ✦ | 1.66K | Nieuw | $212,873 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Point72 Asset Management | $33.39M | 0.1% |
| Bridgewater Associates | $6.12M | 0.0% |
| Fisher Asset Management | $212,873 | 0.0% |
Verlaten
| Norges Bank | $395.09M | was 0.0% |
| D. E. Shaw & Co. | $2.43M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1,065 houders, 251.21M aandelen, $26.86B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 634 aand · $95,972
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie